Amaurosis fugax: Associations with heritable thrombophilia

Clinical and Applied Thrombosis/Hemostasis

Volumn 11, Issue 3, 2005, Pages 235-241

  Glueck, C J ^a,b   Goldenberg, Naila ^a   Bell, Howard ^a   Golnik, Karl ^a   Wang, Ping ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b Cholesterol Center   (United States)

Author keywords

Acquired thrombophilia; Amaurosis fugax; Gene environment interaction; Inherited hypofibrinolysis; Inherited thrombophilia; Transient cerebral ischemic attack

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; ESTROGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN S;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ANTICOAGULATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTROGEN BLOOD LEVEL; FAMILIAL DISEASE; FEMALE; GENE MUTATION; HEART ATRIUM FIBRILLATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INTERNAL CAROTID ARTERY; INTRACARDIAC THROMBOSIS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE VENOGRAPHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBOGRAPHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA ARTERY; THROMBOGENESIS; THROMBOPHILIA; TRANSITIONAL BLINDNESS;

ADULT; AGED; AMAUROSIS FUGAX; AMINO ACID SUBSTITUTION; BRAIN; CHILD; FACTOR VIII; FEMALE; HETEROZYGOTE DETECTION; HOMOZYGOTE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; REFERENCE VALUES; THROMBOPHILIA;

EID: 22544441868     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960501100301     Document Type: Article

References (38)

1. Nguyen TN, Gans MS, Cote R. The prognosis of amaurosis fugas and hemispheric transient ischemic attacks. Can J Ophthalmol 1999;34:210.
2. Babikian V, Wijman CA, Koleini B, et al. Retinal ischemia and embolism. Etiologies and outcomes based on a prospective study. Cerebrovasc Dis 2001;12:108.
3. Lawrence PF, Oderich GS. Ophthalmologic findings as predictors of carotid artery disease. Vasc Endovasc Surg 2002;36:415.
4. Iwamoto T, Matsushima C, Shimizu S, et al. Carotid ultrasonographic and brain computerized tomographic findings in patients with vascular ocular syndromes. No To Shinkei 2002;54:119.
5. Donders RC. Dutch TMB Study Group. Clinical features of transient monocular blindness and the likelihood of atherosclerotic lesions of the internal carotid artery. J Neurol Neurosurg Psychiatry 2001;71:247.
6. Tegos TG, Sabetai MM, Nicolaides AN, et al. Patterns of cerebrovascular symptomatology associated with carotid atheroma. Eur J Neurol 2000;7:499.
7. Winterkorn J, Kupersmith MJ, Wirtschafter JD, et al. Treatment of vasospastic amaurosis fugax with calcium-channel blockers. N Engl J Med 1993;329:396.
8. Nesher G. Neurologic manifestations of giant cell arteritis. Clin Exp Rheumatol 2000;18:S24.
9. Vrethem M, Ernerudh J, Lindstrom F, et al. Cerebral ischemia associated with anticardiolipin antibodies. Acta Neurol Scand 1992;85:412.
10. Pope JM, Canny CL, Bell DA. Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant. Am J Med 1991;90:299.
11. Petty GW, Brown RD Jr, Wisnant JP, et al. Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention. A population-based study. Ann Intern Med 1999;130:14.
12. Glueck CJ, Wang P, Bell H, et al. Non-arteritic anterior ischemic optic neuropathy: Associations with homozygosity for the C677T methylenetetrahydrofolate reductase. J Lab Clin Med 2004;143:184.
13. Glueck CJ, Bell H, Vadlamani L, et al. Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. Arch Ophthalmol 1999;117:43.
14. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999;130:643.
15. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999;93:1271.
16. Glueck CJ, Freiberg RA, Fontaine RN, et al. Hypofibrinolysis, Thrombophilia, Osteonecrosis. Clin Orthop 2001;386:19.
17. Glueck CJ, Kupferminc MJ, Fontaine RN, et al. Genetic hypofibrinolysis in complicated pregnancies. Obstet Gynecol 2001;97:44.
18. Glueck CJ, Iyengar S, Goldenberg N, et al. Pseudotumor cerebri: Associations with coagulation disorders and polycystic ovary syndrome. J Lab Clin Med 2003;142:35.
19. Balasa VV, Gruppo RA, Glueck CJ, et al. The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and plasminogen activator inhibitor-1 levels in children and adults. Thromb Haemost 1999;81:739.
20. Glueck CJ, Fontaine RN, Wang P. Interaction of heritable and estrogen-induced thrombophilia: Possible etiologies for ischemic optic neuropathy and ischemic stroke. Thromb Haemost 2001;85:256.
21. Glueck CJ, Glueck HI, Tracy T, et al. Relationships between lipoprotein (a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. Metabolism 1993;42:236.
22. SAS Release 8. SAS Institute, SAS Circle, Box 8000, Cary NC 27512-8000.
23. Zelterman D. Advanced log-linear models using SAS. 2002. SAS Institute Inc, Cary NC, 27512-8000.
24. Palmowski AM, Ruprecht KW. Amaurosis fugax. Fortschr Med 1992;110:531.
25. Derieux L, Gouomard JL, Catier A, et al. Fibrinolysis in the treatment of the amaurosis fugax: A case report. Fr Ophthalmol 2003;26:507.
26. Bick RL, Alfar H, Goedecke C. Thrombophilic causes of retinal vascular thrombosis: Etiology and treatment outcomes. Clin Appl Thromb Hemost 2002;8:315.
27. Goertler M, Blaser T, Krueger S, et al. Cessation of embolic signals after antithrombotic prevention is related to reduced risk of recurrent arterioembolic transient ischaemic attack and stroke. J Neurol Neurosurg Psychiatry 2002;72:338.
28. Eriksson SE. Enteric-coated acetylsalicylic acid plus dipyridamole compared to anticoagulants in the prevention of ischemic events in patients with transient ischemic attacks. Acta Neurol Scand 1985;71:485.
29. Olsson JE, Brechter C, Backlund H, et al. Anticoagulant vs anti-platelet therapy as prophylactic against cerebral infarction in transient ischemic attacks. Stroke 1980;11:4.
30. Greiner K, Peetz D, Winkgen A, et al. Genetic thrombophilia in patients with retinal vascular occlusion. Int Ophthalmol 1999;23:155.
31. Soria JM, Almasy L, Souto JC, et al. A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility. Blood 2003;101:163.
32. Graf LL, Welsh CH, Qamar Z, et al. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden. Am J Clin Pathol 2003;119:52.
33. Elishkewitch K, Berliner S, Eldor A, et al. High factor VIII as risk factor for venous thrombosis. Harefuah 2001;140:1122.
34. Cakmak S, Derex L, Berruyer M, et al. Cerebral venous thrombosis: Clinical outcome and systematic screening of prothrombotic disorders. Neurology 2003;60:1175.
35. Keijzer MB, den Heijer M, Blom HJ, et al. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolate reductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost 2002;88:723.
36. Bleomenkamp KW, Helmerhorst FM, Rosendaal FR, et al. Thrombophilias and gynaecology. Best Pract Res Clin Obstet Gynaecol 2003;17:509.
37. Szolnoki Z, Somogyvari F, Kondacs A, et al. Evaluation of the modifying effects of unfavorable genotypes on clinical risk factors for ischemic stroke. J Neurol Neurosurg Psychiatry. 2003;74:1615.
38. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723.